戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 help guide molecular interventions in ocular von Hippel-Lindau disease.
2 of these mutants may rescue pVHL function in von Hippel-Lindau disease.
3 cal characterization and treatment of ocular von Hippel-Lindau disease.
4 ogenesis, which can occur sporadically or in von Hippel-Lindau disease.
5 role in the pathogenesis of renal cancer and von Hippel-Lindau disease.
6 pects, management, and treatment options for von Hippel-Lindau disease.
7  familial disposition to pheochromocytoma in von Hippel-Lindau disease.
8 hromocytoma should be screened for MEN-2 and Von Hippel-Lindau disease.
9  the familial cancer predisposition syndrome von Hippel-Lindau disease.
10  hemangioma with or without association with von Hippel-Lindau disease.
11 rmline mutation in the VHL gene leads to the von Hippel-Lindau disease, a familial syndrome character
12 suppressor protein (pVHL) is associated with von Hippel-Lindau disease, an inherited cancer syndrome,
13                  We studied 26 patients with von Hippel-Lindau disease and 9 patients with MEN-2 who
14  hereditary renal cancers in adults included von Hippel-Lindau disease and a rare form of chromosomal
15 hatic sac tumors (ELSTs) are associated with von Hippel-Lindau disease and cause irreversible sensori
16 ctive and serial evaluation of patients with von Hippel-Lindau disease and ELSTs at the National Inst
17                    Thirty-five patients with von Hippel-Lindau disease and ELSTs in 38 ears (3 bilate
18 pressor gene is inactivated in patients with von Hippel-Lindau disease and in most sporadic clear cel
19                                              Von Hippel-Lindau disease and MEN-2 were diagnosed on th
20 tion may be important in the pathogenesis of von Hippel-Lindau disease and RCC.
21 t knowledge of the molecular pathogenesis of von Hippel-Lindau disease and the role of the VHL gene p
22     Two had prior clinical manifestations of von Hippel-Lindau disease and, as expected, had germline
23 sis type 1 (NF1), 444 tuberous sclerosis, 63 von Hippel-Lindau disease, and 39 ataxia-telangiectasia.
24         Multiple endocrine neoplasia type 2, von Hippel-Lindau disease, and familial adenomatous poly
25 pressor gene predisposes patients to develop von Hippel-Lindau disease, and somatic VHL inactivation
26                       Patients affected with von Hippel-Lindau disease are at risk of developing mult
27 f eye disease may inform us as to how ocular von Hippel-Lindau disease arises, and help guide molecul
28 C), as VHL mutations have been found in both von Hippel-Lindau disease-associated and sporadic RCCs.
29                        Adults with 1 or more von Hippel-Lindau disease-associated measurable renal ce
30 -2alpha inhibitor belzutifan is approved for von Hippel-Lindau disease-associated renal cell carcinom
31 f participants with an objective response in von Hippel-Lindau disease-associated renal cell carcinom
32  use of belzutifan as systemic treatment for von Hippel-Lindau disease-associated renal cell carcinom
33 actor (VEGF) mRNA is upregulated in RCC- and von Hippel-Lindau disease-associated tumors.
34 edian follow-up for participants with ocular von Hippel-Lindau disease at baseline was 37.3 months.
35 s aged 18 years or older with a diagnosis of von Hippel-Lindau disease (based on germline VHL alterat
36 erization of renal cancer syndromes includes von Hippel-Lindau disease, Birt-Hogg-Dube syndrome, here
37                                          The von Hippel-Lindau disease gene (VHL) is the causative ge
38                             One patient with von Hippel-Lindau disease had a normal plasma normetanep
39 s of metanephrine, whereas the patients with von Hippel-Lindau disease had almost exclusively high pl
40 titative clinical characterization of ocular von Hippel-Lindau disease has been limited by small pati
41                    Genetic testing confirmed von Hippel-Lindau disease in 8 of 17 patients (47%).
42 fan showed promising activity against ocular von Hippel-Lindau disease, including capacity to control
43                                              von Hippel-Lindau disease is a hereditary cancer syndrom
44                                              von Hippel-Lindau disease is a heritable multisystem can
45                                              von Hippel-Lindau disease is an inherited, multisystemic
46 ble a full characterization of the impact of von Hippel-Lindau disease on eye health and visual funct
47                     Twenty-one patients with von Hippel-Lindau disease or hereditary papillary renal
48 ified pheochromocytomas and 50 patients with von Hippel-Lindau disease or MEN-2 who had no radiologic
49 detecting pheochromocytomas in patients with von Hippel-Lindau disease or MEN-2.
50 risk for these tumors, such as patients with von Hippel-Lindau disease or multiple endocrine neoplasi
51 plasia type 2, von Recklinghausen's disease, von Hippel-Lindau disease, or Carney's syndrome.
52 s performed on postmortem tissues from three von Hippel-Lindau disease patients (not in the clinical
53  correlated with the clinical findings in 16 von Hippel-Lindau disease patients with 22 CNS hemangiob
54 netic resonance imaging (MRI) is obtained in von Hippel-Lindau disease patients, hemangioblastomas pr
55 ularly US screening studies in patients with von Hippel-Lindau disease should be interpreted cautious
56 therapies targeting the molecular biology of von Hippel-Lindau disease, some of which are presently b
57                                              von Hippel-Lindau disease (VHL [MIM 193300]) is a herita
58 o other causes of inherited renal carcinoma, von Hippel-Lindau disease (VHL) and the chromosome trans
59                                Patients with von Hippel-Lindau disease (VHL) are at risk to develop m
60 atures that meet the diagnostic criteria for von Hippel-Lindau disease (VHL) have a detectable inacti
61                                              von Hippel-Lindau disease (VHL) is a dominantly inherite
62                                              von Hippel-Lindau disease (VHL) is an autosomal-dominant
63 euroendocrine tumors (PNETs) associated with von Hippel-Lindau disease (VHL) is challenging because o
64                                              Von Hippel-Lindau disease (VHL) is one of the most commo
65                                              von Hippel-Lindau disease (VHL) patients develop highly
66 dromes, multiple endocrine neoplasia type 2, von Hippel-Lindau disease (VHL), and, very rarely, type
67 uses of phaeochromocytoma susceptibility are von Hippel-Lindau disease (VHL), multiple endocrine neop
68  examined the promoter methylation status of von Hippel-Lindau disease (VHL), retinoic acid receptor
69 tremely rare in the general population, with von Hippel-Lindau disease (VHL).
70 ents with clinically and genetically defined von Hippel-Lindau disease was systemically characterized
71 tions of the VHL tumor suppressor gene cause von Hippel-Lindau disease, which is associated with an i